Rajabali Daroudi1,2, Mehrzad Mirzania3, Kazem Zendehdel1,4. 1. Cancer Research Center, Cancer Institute of Iran, Tehran University Sciences, Tehran, Iran. 2. Department of Health Economics and Management, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3. Hematology and Medical Oncology Department, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. 4. Cancer Model Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some economic aspects of new cancer drugs. METHODS: We translated a questionnaire that was used in similar studies in the United States and Canada into Persian and modified it according to the local setting in Iran. The face and content validity of the questionnaire were assessed by oncologists before being used in the survey. We distributed the questionnaire and collected the data from 80 oncologists who participated in the 13th Annual Congress of the Iranian Society of Medical Oncology and Hematology (ISMOH). RESULTS: Fifty-two oncologists participated in our study (a response rate of 65%). The majority of oncologists stated that drug costs and patient out-of-pocket (OOP) costs influence their treatment recommendations (92% and 94%, respectively). Most oncologists (70%) felt that they are ready enough to use cost-effectiveness information in their treatment decisions, and 74% believed that patients should only have access to cancer treatments that are cost-effective. Most oncologists agree that the government should have control over drug prices, and more use of cost-effectiveness data is required for decision-making about cancer drug coverage. Ninety-one percent of oncologists said that they always or frequently discuss cancer treatment costs with their patients. Oncologists believed that academic groups (research centers and scientific societies) (81%) and the Ministry of Health (MoH) (43%) are the most eligible groups for determining whether a drug provides good value. CONCLUSION: Iranian medical oncologists are ready to participate in the health technology assessment and priority-setting process. This situation creates a unique opportunity for the government to rely on scientific societies and find an appropriate solution for the improvement of patients' access to high-quality care.
BACKGROUND: Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some economic aspects of new cancer drugs. METHODS: We translated a questionnaire that was used in similar studies in the United States and Canada into Persian and modified it according to the local setting in Iran. The face and content validity of the questionnaire were assessed by oncologists before being used in the survey. We distributed the questionnaire and collected the data from 80 oncologists who participated in the 13th Annual Congress of the Iranian Society of Medical Oncology and Hematology (ISMOH). RESULTS: Fifty-two oncologists participated in our study (a response rate of 65%). The majority of oncologists stated that drug costs and patient out-of-pocket (OOP) costs influence their treatment recommendations (92% and 94%, respectively). Most oncologists (70%) felt that they are ready enough to use cost-effectiveness information in their treatment decisions, and 74% believed that patients should only have access to cancer treatments that are cost-effective. Most oncologists agree that the government should have control over drug prices, and more use of cost-effectiveness data is required for decision-making about cancer drug coverage. Ninety-one percent of oncologists said that they always or frequently discuss cancer treatment costs with their patients. Oncologists believed that academic groups (research centers and scientific societies) (81%) and the Ministry of Health (MoH) (43%) are the most eligible groups for determining whether a drug provides good value. CONCLUSION: Iranian medical oncologists are ready to participate in the health technology assessment and priority-setting process. This situation creates a unique opportunity for the government to rely on scientific societies and find an appropriate solution for the improvement of patients' access to high-quality care.
Authors: J Thomson; P Schofield; L Mileshkin; E Agalianos; J Savulescu; J Zalcberg; M Jefford Journal: Ann Oncol Date: 2006-01-17 Impact factor: 32.976
Authors: Peter J Neumann; Jennifer A Palmer; Eric Nadler; Chihui Fang; Peter Ubel Journal: Health Aff (Millwood) Date: 2010 Jan-Feb Impact factor: 6.301
Authors: G Caleb Alexander; Lawrence P Casalino; Chien-Wen Tseng; Diane McFadden; David O Meltzer Journal: J Gen Intern Med Date: 2004-08 Impact factor: 5.128
Authors: Susanne J de Kort; Nuala Kenny; Paul van Dijk; Sjef Gevers; Dick J Richel; Dick L Willems Journal: Eur J Cancer Date: 2007-07-09 Impact factor: 9.162
Authors: Neal J Meropol; Deborah Schrag; Thomas J Smith; Therese M Mulvey; Robert M Langdon; Diane Blum; Peter A Ubel; Lowell E Schnipper Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Lesley Chim; Glenn Salkeld; Patrick Kelly; Wendy Lipworth; Dyfrig A Hughes; Martin R Stockler Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240